Litigation Details for The Medicines Company v. Exela Pharma Sciences, LLC (W.D.N.C. 2014)

« Back to Dashboard

The Medicines Company v. Exela Pharma Sciences, LLC (W.D.N.C. 2014)

Docket		Date Filed	2014-04-25
Court	District Court, W.D. North Carolina	Date Terminated	2018-03-26
Cause	15:1126 Patent Infringement	Assigned To	Robert James Conrad Jr.
Jury Demand	None	Referred To	David S. Cayer
Patents	7,582,727; 7,598,343
Link to Docket	External link to docket

Details for The Medicines Company v. Exela Pharma Sciences, LLC (W.D.N.C. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-04-25				External link to document

The Medicines Company v. Exela Pharma Sciences, LLC, 5:14-cv-00058: Litigation Summary and Patent Analysis

Last updated: November 13, 2026

The Medicines Company sued Exela Pharma Sciences in the U.S. District Court for the Eastern District of North Carolina after Exela submitted an abbreviated new drug application seeking approval to market generic bivalirudin for injection, the active pharmaceutical ingredient in Angiomax. The case concerned U.S. Patent No. 7,582,727, which covered pharmaceutical batches of bivalirudin with controlled impurity levels.

The action was resolved without a reported merits decision. Public docket materials indicate that the parties filed a joint dismissal, ending the case before trial. The settlement terms were not publicly disclosed. The case therefore provides limited precedent on the validity or infringement of the asserted patent, but it remains relevant to generic-entry timing and the commercial protection of Angiomax.

What patents did The Medicines Company assert against Exela?

The principal asserted patent was U.S. Patent No. 7,582,727, titled “Pharmaceutical Batches of Bivalirudin.” The patent was assigned to The Medicines Company and listed in the FDA Orange Book for Angiomax.

Patent	Subject matter	Patent holder	Drug	Litigation status
U.S. 7,582,727	Pharmaceutical batches of bivalirudin with specified impurity characteristics	The Medicines Company	Angiomax, bivalirudin for injection	Asserted against Exela; case dismissed after settlement

The patent focused on the quality and composition of manufactured bivalirudin batches rather than a new chemical entity. Its claims addressed the presence and control of impurities generated during manufacture. The patent was commercially important because a generic applicant could need to develop a manufacturing process that avoided the claimed batch characteristics while still satisfying FDA quality requirements.

The patent issued on September 1, 2009. Public Orange Book records associated the patent with an expiration date in December 2028, subject to the applicable patent-term calculation and any recorded term adjustments. The patent’s asserted claims were therefore capable of delaying or restricting generic competition well beyond Angiomax’s original regulatory exclusivity period.

What was the procedural history of The Medicines Company v. Exela?

The Medicines Company filed the action in 2014 after receiving Exela’s Paragraph IV certification challenging the Orange Book-listed patent. The case was assigned civil action number 5:14-cv-00058 in the Eastern District of North Carolina.

Event	Date or period	Significance
Exela submits ANDA and Paragraph IV certification	Before February 2014	Triggered the patent dispute
The Medicines Company files suit	2014	Initiated the Hatch-Waxman action
District court proceedings	2014	Focused on infringement, validity and generic approval risk
Joint dismissal and settlement	2014 or thereafter	Ended the action without a reported merits ruling

A Hatch-Waxman patent action filed within 45 days after receipt of a Paragraph IV notice generally creates a statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii). The docket and public case records should be read together with FDA approval records to determine whether the stay was terminated, expired, or superseded by a settlement arrangement.

The case did not produce a published claim-construction order, summary-judgment ruling, bench-trial opinion, or Federal Circuit decision addressing the patent’s validity or infringement against Exela. The dismissal therefore provides no judicial holding that Exela’s proposed product infringed, or did not infringe, the asserted claims.

What was the central patent dispute over bivalirudin manufacturing?

The dispute centered on whether Exela’s proposed generic bivalirudin product would be made using a process that resulted in pharmaceutical batches falling within the claims of U.S. Patent No. 7,582,727.

Bivalirudin is a synthetic anticoagulant peptide. The manufacturing process can generate impurities and degradation products that affect product quality. The Medicines Company’s patent position relied on controlling those impurities through manufacturing conditions, purification steps, and batch specifications.

The technical questions likely included:

1. Whether Exela’s ANDA product would contain the claimed impurity profile.
2. Whether the patent claims required a particular manufacturing process or only a resulting batch composition.
3. Whether the asserted claims were anticipated or rendered obvious by prior bivalirudin manufacturing disclosures.
4. Whether the patent adequately described and enabled the claimed pharmaceutical batches.
5. Whether Exela’s ANDA process and product information supported a finding of infringement under 35 U.S.C. § 271(e)(2).

These issues differ from a conventional formulation dispute. The patent did not principally protect a tablet, injectable excipient system, or delivery device. Its value was tied to the manufacturing and quality attributes of the active pharmaceutical product.

What was the Orange Book status of Angiomax and bivalirudin?

Angiomax was approved by the FDA as an injectable anticoagulant containing bivalirudin. The Medicines Company listed U.S. Patent No. 7,582,727 in the Orange Book for the product.

The regulatory and patent positions were separate:

Protection type	Relevance to Exela
NDA approval for Angiomax	Established the reference listed drug
Orange Book patent listing	Allowed The Medicines Company to receive Paragraph IV notice
Paragraph IV certification	Created the basis for patent litigation
30-month stay	Potentially delayed FDA approval of Exela’s ANDA
Patent expiration	Defined the outside date for the asserted patent barrier, absent invalidity, noninfringement, licensing or settlement

Angiomax did not have biologic status. It was a chemically synthesized peptide drug regulated through the conventional ANDA pathway. Biosimilar rules under the Public Health Service Act did not apply. The principal competitive threat was therefore a generic injectable, not a biosimilar.

Did Exela file a Paragraph IV challenge?

Yes. The lawsuit was a Hatch-Waxman action arising from Exela’s ANDA and Paragraph IV certification concerning bivalirudin for injection.

A Paragraph IV certification asserts that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Filing suit within the statutory period permits the brand company to invoke the automatic approval stay.

The public record does not establish a final judicial determination on the specific Paragraph IV theories advanced by Exela. Because the case ended without a merits opinion, the following issues remain unresolved in this action:

• Whether Exela’s proposed manufacturing process infringed the asserted claims.
• Whether the patent survived anticipation and obviousness challenges.
• Whether any asserted claims were invalid for inadequate written description or enablement.
• Whether the patent was enforceable against Exela.
• Whether Exela obtained a licensed or otherwise authorized launch date.

What was the litigation outcome and settlement status?

The case ended through a joint dismissal rather than a trial judgment. The publicly available record does not disclose the commercial terms of the parties’ agreement.

A settlement in a generic patent case can address several issues, including:

• The date on which the generic may launch.
• Whether the generic can launch before patent expiration under a license.
• Supply, distribution or manufacturing restrictions.
• Patent withdrawal or amendment.
• Covenants not to sue.
• Exclusivity allocation between multiple ANDA applicants.

The dismissal alone does not establish that Exela was permitted to launch immediately. It also does not establish that The Medicines Company prevailed on infringement or that Exela prevailed on invalidity. Any launch-date conclusion must be based on FDA approval history, product-label records, subsequent commercial activity and any publicly filed settlement materials.

No publicly reported FTC or DOJ challenge to the settlement has been identified in the case record. The absence of an enforcement action does not disclose the substantive terms of the agreement.

How strong was The Medicines Company’s patent estate against Exela?

The patent estate was commercially meaningful but technically vulnerable because it depended on manufacturing and impurity limitations.

Strengths

• U.S. Patent No. 7,582,727 had a late expiration date relative to Angiomax’s market launch.
• The patent was listed in the Orange Book.
• The claimed subject matter related to product quality attributes that could be difficult to avoid while meeting FDA specifications.
• A Paragraph IV filing created a statutory pathway for delaying ANDA approval.
• The patent had already been asserted in disputes involving other generic manufacturers, increasing its commercial significance.

Weaknesses

• Manufacturing-process and batch-composition claims can face anticipation and obviousness challenges.
• Infringement may depend on confidential ANDA manufacturing information.
• A generic applicant may design around the claimed impurity profile or process conditions.
• A settlement without a merits ruling left the patent’s enforceability and infringement strength untested against Exela.
• The commercial value of a process patent declines if alternative manufacturing routes are available.

The case should therefore be classified as a significant Orange Book dispute with an unresolved merits record, rather than as a validated judicial victory for either party.

How did this case compare with other Angiomax patent litigation?

The Exela dispute was part of a broader patent campaign involving generic bivalirudin. The Medicines Company also litigated the same general patent family against other generic manufacturers, including Hospira.

The most important distinction is procedural outcome. In other litigation, courts examined whether a generic manufacturer’s process produced batches within the scope of the patent claims. In The Medicines Company v. Hospira, the Federal Circuit addressed issues involving infringement of the bivalirudin manufacturing patent. The Exela case did not generate an equivalent merits decision.

Issue	Exela case	Other Angiomax litigation
Drug	Bivalirudin for injection	Bivalirudin for injection
Regulatory pathway	ANDA	ANDA
Core patent issue	Batch composition and manufacturing	Batch composition and manufacturing
Trial or appellate merits ruling	No reported ruling	Some cases produced substantive rulings
Public settlement terms	Not disclosed	Varied by case
Precedential value	Limited	Greater where appellate decisions issued

The absence of a final opinion in the Exela action means that its primary value is as evidence of generic-entry pressure and settlement behavior, not as controlling authority on claim scope.

What generic-entry risks did Exela create for Angiomax?

Exela presented four principal risks to The Medicines Company:

1. Price erosion. Approval of a generic injectable could reduce Angiomax pricing and hospital account retention.
2. Formulary substitution. Hospitals could shift purchasing to an FDA-approved generic without waiting for a full clinical substitution process.
3. Manufacturing competition. Exela’s ability to produce compliant bivalirudin could weaken the value of the patented manufacturing method.
4. Follow-on challenges. A successful Exela launch could encourage additional ANDA applicants to challenge the same Orange Book patent.

For Exela, the main risks were litigation cost, delayed approval, possible damages for an at-risk launch, and the need to maintain a manufacturing process that avoided infringement while meeting injectable-drug quality standards.

Did the case involve formulation patents, method-of-use patents or biosimilar issues?

The litigation was principally a manufacturing and pharmaceutical-batch patent dispute.

There is no indication from the public case description that the central claims involved:

• A separate injectable formulation patent.
• A device or delivery-system patent.
• A clinical method-of-use patent.
• A biologic or biosimilar approval pathway.
• A patent covering a new bivalirudin indication.

The regulatory dispute was therefore narrower than a typical branded-drug patent estate involving composition, formulation, method-of-use and manufacturing patents in parallel.

What is the commercial significance of the Exela case?

The case demonstrates how a single Orange Book-listed manufacturing patent can support litigation against generic injectable entrants even after a drug’s core regulatory exclusivity has ended.

For The Medicines Company, the asserted patent potentially protected Angiomax revenue through 2028. For Exela, the value of a successful Paragraph IV challenge depended on whether the generic could launch before patent expiration and secure hospital contracts. The undisclosed settlement terms prevent a precise calculation of the economic transfer between the parties.

The principal commercial conclusion is that the patent created negotiating leverage but did not receive a final judicial test in the Exela action. Its practical value depended on the availability of noninfringing manufacturing routes, the FDA’s approval timing, and the settlement’s launch provisions.

Key Takeaways

• The Medicines Company sued Exela in 2014 over an ANDA for generic bivalirudin for injection.
• The principal patent was U.S. Patent No. 7,582,727, covering pharmaceutical batches of bivalirudin.
• The case was a Paragraph IV Hatch-Waxman action.
• The dispute focused on manufacturing and impurity characteristics, not biosimilar substitution.
• The case ended by joint dismissal without a reported merits decision.
• Settlement terms and any agreed generic launch date were not publicly disclosed.
• The litigation did not establish whether Exela infringed, or whether the asserted patent was valid and enforceable.
• The patent’s Orange Book listing gave The Medicines Company a substantial procedural and commercial advantage.
• The case should be treated as an unresolved patent-strength signal rather than a merits precedent.

FAQs About The Medicines Company v. Exela

Was Exela allowed to launch generic bivalirudin before the patent expired?

The public dismissal record does not disclose the settlement’s launch provisions. FDA approval and commercial launch records must be separated from the fact of dismissal.

Which FDA-approved product did Exela challenge?

Exela challenged Angiomax, the reference product containing bivalirudin for injection.

Was U.S. Patent No. 7,582,727 a formulation patent?

No. The patent principally addressed pharmaceutical batches of bivalirudin and related impurity or quality characteristics arising from manufacture.

Did the case establish that the bivalirudin patent was valid?

No. The action ended without a reported validity ruling.

Can The Medicines Company rely on this case against later generic applicants?

Only to the extent that the case shows prior enforcement of the Orange Book-listed patent. Because there was no merits decision, the dismissal has limited precedential value on claim construction, validity or infringement.

References

1. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

2. The Medicines Company v. Exela Pharma Sciences, LLC, No. 5:14-cv-00058 (E.D.N.C. 2014). Public docket records.

3. U.S. Patent No. 7,582,727. (2009). Pharmaceutical batches of bivalirudin. U.S. Patent and Trademark Office.

4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application regulations and patent certifications. U.S. Department of Health and Human Services.

5. The Medicines Co. v. Hospira, Inc., 827 F.3d 1363 (Fed. Cir. 2016).